iShares Biotechnology ETF
414 hedge funds and large institutions have $3.86B invested in iShares Biotechnology ETF in 2016 Q1 according to their latest regulatory filings, with 67 funds opening new positions, 130 increasing their positions, 143 reducing their positions, and 75 closing their positions.
New
Increased
Maintained
Reduced
Closed
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less funds holding
Funds holding: →
less first-time investments, than exits
New positions opened: | Existing positions closed:
less call options, than puts
Call options by funds: $ | Put options by funds: $
34% less funds holding in top 10
Funds holding in top 10: 32 → 21 (-11)
36% less capital invested
Capital invested by funds: $6B → $3.86B (-$2.14B)
Holders
414
Holding in Top 10
21
Calls
$608M
Puts
$901M
Top Buyers
| 1 | +$132M | |
| 2 | +$110M | |
| 3 | +$65.3M | |
| 4 |
Two Sigma Advisers
New York
|
+$51.4M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
+$49.6M |
Top Sellers
| 1 | -$447M | |
| 2 | -$177M | |
| 3 | -$116M | |
| 4 |
Morgan Stanley
New York
|
-$108M |
| 5 |
Wells Fargo
San Francisco,
California
|
-$92.4M |